KARMANOS CANCER HOSPITAL
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230297
- Received
- $13,755,007 in 2,821 records, 2019 ($110,045 general, $13,644,962 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 12 | $110,045 |
| 2019 | Research payment | 2,809 | $13,644,962 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,809 | $13,644,962 |
| Grant | 3 | $79,000 |
| Space rental or facility fees (teaching hospital only) | 5 | $22,500 |
| Charitable Contribution | 2 | $5,500 |
| Education | 2 | $3,045 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Merck Sharp & Dohme LLC | $5,452 | Research payment | In-kind items and services | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $4,530 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2019 |
| 2019-12-31 | Merck Sharp & Dohme LLC | $4,481 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $3,561 | Research payment | In-kind items and services | Ph2a Montherapy RCC study | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,655 | Research payment | In-kind items and services | Phase I dose escalation and expansion to establish tolerated combination of AZD2014 palbociclib and fulvestrant triplet | 2019 | |
| 2019-12-31 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2019 |
| 2019-12-31 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Phase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-1 | 2019 |
| 2019-12-31 | Merck Sharp & Dohme LLC | $545 | Research payment | In-kind items and services | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $300 | Research payment | In-kind items and services | Study of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $37 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squa | 2019 |
| 2019-12-31 | AstraZeneca UK Limited | $34 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $12 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2019 |
| 2019-12-30 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-12-30 | Janssen Research & Development, LLC | $2,643 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $1,631 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $1,384 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $608 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $398 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $68 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2019 | |
| 2019-12-27 | Merck Sharp & Dohme LLC | $9,808 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2019 |
| 2019-12-27 | Merck Sharp & Dohme LLC | $8,178 | Research payment | In-kind items and services | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
| 2019-12-27 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and | 2019 |
| 2019-12-27 | Merck Sharp & Dohme LLC | $990 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R | 2019 |
| 2019-12-27 | Merck Sharp & Dohme LLC | $818 | Research payment | In-kind items and services | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
| 2019-12-23 | Genentech, Inc. | $54,047 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2019 |
| 2019-12-23 | Exelixis Inc. | $10,925 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-12-23 | Merck Sharp & Dohme LLC | $10,826 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2019 |
| 2019-12-23 | Exelixis Inc. | $3,069 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-12-23 | Exelixis Inc. | $1,950 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-12-23 | Janssen Research & Development, LLC | $1,699 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-23 | Exelixis Inc. | $1,144 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-12-23 | Genentech, Inc. | $800 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2019 |
| 2019-12-20 | Genentech, Inc. | $4,150 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2019 |
| 2019-12-20 | Genentech, Inc. | $3,700 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2019 |
| 2019-12-20 | Genentech, Inc. | $3,385 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-12-20 | Merck Sharp & Dohme LLC | $97 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemother | 2019 |
| 2019-12-19 | Kite Pharma, Inc. | $27,584 | Research payment | Cash or cash equivalent | Yescarta Drug, ONC | PA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non | 2019 |
| 2019-12-19 | Merck Sharp & Dohme LLC | $27,065 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli | 2019 |
| 2019-12-19 | Alkermes, Inc. | $25,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $25,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $25,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $25,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $25,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $23,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $6,057 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | PUMA BIOTECHNOLOGY, INC. | $1,000 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | 2019 |
| 2019-12-19 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-9343 Solid Tumor Multi Cohort Trial | 2019 |
| 2019-12-19 | Janssen Research & Development, LLC | $920 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2019 | |
| 2019-12-19 | Janssen Research & Development, LLC | $811 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2019 | |
| 2019-12-19 | Alkermes, Inc. | $792 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Merck Sharp & Dohme LLC | $400 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2019 |
| 2019-12-19 | Pharmacyclics LLC, an AbbVie Company | $336 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1128-CA | 2019 |
| 2019-12-19 | Alkermes, Inc. | $300 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-19 | Regeneron Pharmaceuticals, Inc. | $106 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-12-19 | Alkermes, Inc. | $62 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-18 | SEAGEN INC. | $16,950 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Abov | 2019 |
| 2019-12-18 | Regeneron Pharmaceuticals, Inc. | $7,237 | Research payment | Cash or cash equivalent | Phase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multipl | 2019 | |
| 2019-12-18 | Alkermes, Inc. | $3,700 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-12-18 | Regeneron Pharmaceuticals, Inc. | $2,059 | Research payment | Cash or cash equivalent | Phase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multipl | 2019 | |
| 2019-12-18 | Regeneron Pharmaceuticals, Inc. | $1,119 | Research payment | Cash or cash equivalent | Phase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multipl | 2019 | |
| 2019-12-18 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | Phase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multipl | 2019 | |
| 2019-12-18 | Merck Sharp & Dohme LLC | $798 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous | 2019 |
| 2019-12-18 | Merck Sharp & Dohme LLC | $342 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous | 2019 |
| 2019-12-18 | Merck Sharp & Dohme LLC | $244 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2019 |
| 2019-12-17 | Merck Sharp & Dohme LLC | $6,500 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli | 2019 |
| 2019-12-17 | BIOVERATIV THERAPEUTICS INC. | $4,343 | Research payment | Cash or cash equivalent | BIVV003 Drug | A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantati | 2019 |
| 2019-12-17 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli | 2019 |
| 2019-12-17 | Corcept Therapeutics | $98 | Research payment | Cash or cash equivalent | CORT125281-601 | 2019 | |
| 2019-12-16 | Bayer Healthcare Pharmaceuticals Inc. | $3,856 | Research payment | Cash or cash equivalent | Non-Covered | BAY1163877 I/O combination in Urothelial Bladder Cancer | 2019 |
| 2019-12-16 | Bayer Healthcare Pharmaceuticals Inc. | $2,132 | Research payment | Cash or cash equivalent | Non-Covered | BAY1163877 I/O combination in Urothelial Bladder Cancer | 2019 |
| 2019-12-16 | Bayer Healthcare Pharmaceuticals Inc. | $1,623 | Research payment | Cash or cash equivalent | Non-Covered | BAY1163877 I/O combination in Urothelial Bladder Cancer | 2019 |
| 2019-12-16 | Eisai Inc. | $1,451 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-12-16 | PUMA BIOTECHNOLOGY, INC. | $1,200 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | 2019 |
| 2019-12-16 | Janssen Research & Development, LLC | $1,155 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 | 2019 | |
| 2019-12-16 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY1163877 I/O combination in Urothelial Bladder Cancer | 2019 |
| 2019-12-16 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A | 2019 |
| 2019-12-16 | Merck Sharp & Dohme LLC | $975 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A | 2019 |
| 2019-12-16 | Merck Sharp & Dohme LLC | $646 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2019 |
| 2019-12-16 | Bayer Healthcare Pharmaceuticals Inc. | $608 | Research payment | Cash or cash equivalent | Non-Covered | BAY1163877 I/O combination in Urothelial Bladder Cancer | 2019 |
| 2019-12-13 | Janssen Research & Development, LLC | $1,998 | Research payment | Cash or cash equivalent | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | 2019 | |
| 2019-12-13 | EMD Serono, Inc. | $1,713 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | EMR 100070-001 | 2019 |
| 2019-12-13 | Regeneron Pharmaceuticals, Inc. | $1,020 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, | 2019 |
| 2019-12-13 | Plexxikon Inc. | $330 | Research payment | Cash or cash equivalent | A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors | 2019 | |
| 2019-12-13 | Plexxikon Inc. | $325 | Research payment | Cash or cash equivalent | PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors | 2019 | |
| 2019-12-12 | Alkermes, Inc. | $75,511 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-12 | F. Hoffmann-La Roche AG | $8,186 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ATEZOLIZUMAB RADIUM IN CASTRATE RESISTANT PROSTATE CANCER | 2019 |
| 2019-12-12 | PFIZER INC. | $1,998 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-12 | Janssen Research & Development, LLC | $1,814 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subject | 2019 | |
| 2019-12-12 | Merck Sharp & Dohme LLC | $1,505 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2019 |
| 2019-12-12 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2019 |
| 2019-12-12 | Focal Therapeutics, Inc. | $750 | Research payment | Cash or cash equivalent | DXA System Device, Breast and Skeletal Health | 17-02 | 2019 |
| 2019-12-12 | Merck Sharp & Dohme LLC | $231 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2019 |
| 2019-12-12 | Incyte Corporation | $125 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 | |
| 2019-12-11 | Alkermes, Inc. | $82,143 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-12-11 | Celgene Corporation | $66,987 | Research payment | Cash or cash equivalent | JCAR017 Drug | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-e | 2019 |
| 2019-12-11 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | PHASE 12 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NE | 2019 |
| 2019-12-11 | Advanced Accelerator Applications | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lutathera Drug, Radioactive targeted therapy - Neuroendocrine tumors | 2019 | |
| 2019-12-11 | Merck Sharp & Dohme LLC | $918 | Research payment | Cash or cash equivalent | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
| 2019-12-11 | Merck Sharp & Dohme LLC | $305 | Research payment | Cash or cash equivalent | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
| 2019-12-11 | Merck Sharp & Dohme LLC | $150 | Research payment | Cash or cash equivalent | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
| 2019-12-10 | Genentech, Inc. | $158 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-12-09 | Clovis Oncology, Inc. | $2,191 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2019 |
| 2019-12-09 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-12-09 | SEAGEN INC. | $1,000 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-12-09 | SEAGEN INC. | $650 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2019 | |
| 2019-12-06 | Janssen Research & Development, LLC | $54,660 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Merck Sharp & Dohme LLC | $21,652 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2019 |
| 2019-12-06 | Janssen Research & Development, LLC | $2,091 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Janssen Research & Development, LLC | $2,035 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Janssen Research & Development, LLC | $2,007 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Janssen Research & Development, LLC | $2,000 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Janssen Research & Development, LLC | $1,384 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Genentech, Inc. | $845 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2019 |
| 2019-12-06 | Janssen Research & Development, LLC | $340 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Alkermes, Inc. | $175 | Research payment | In-kind items and services | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-06 | Alkermes, Inc. | $123 | Research payment | In-kind items and services | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2019 | |
| 2019-12-06 | Janssen Research & Development, LLC | $105 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2019 | |
| 2019-12-05 | PFIZER INC. | $16,783 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2019 |
| 2019-12-05 | Genentech, Inc. | $7,561 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2019 |
| 2019-12-05 | Genentech, Inc. | $5,977 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH II PLACEBO CONTROLLED OF MTIG7192A AND ATEZO IN NSCLC | 2019 |
| 2019-12-05 | TESARO, Inc. | $2,554 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 12 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NE | 2019 |
| 2019-12-05 | ARRAY BIOPHARMA INC | $1,615 | Research payment | Cash or cash equivalent | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | 2019 | |
| 2019-12-05 | Halozyme Inc | $1,500 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-05 | Exelixis Inc. | $1,000 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2019 |
| 2019-12-04 | Merck Sharp & Dohme LLC | $16,239 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli | 2019 |
| 2019-12-04 | Ipsen Biopharmaceuticals, Inc | $4,879 | Research payment | Cash or cash equivalent | SOMATULINE DEPOT Drug, Oncology/Endocrinology | A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide AutogelDep | 2019 |
| 2019-12-04 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-12-04 | SEAGEN INC. | $1,320 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-12-04 | SEAGEN INC. | $1,000 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o | 2019 | |
| 2019-12-04 | SEAGEN INC. | $1,000 | Research payment | Cash or cash equivalent | A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc | 2019 | |
| 2019-12-04 | Merck Sharp & Dohme LLC | $75 | Research payment | Cash or cash equivalent | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
| 2019-12-03 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-12-03 | PFIZER INC. | $20,094 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2019 |
| 2019-12-03 | Genentech, Inc. | $7,333 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2019 |
| 2019-12-03 | Merck Sharp & Dohme LLC | $4,946 | Research payment | Cash or cash equivalent | MK-6482 Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Renal Cell Carcinoma | 2019 |
| 2019-12-03 | Celgene Corporation | $3,711 | Research payment | Cash or cash equivalent | Reblozyl Drug, Beta Thalassemia | A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes ( | 2019 |
| 2019-12-03 | PFIZER INC. | $3,428 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2019 |
| 2019-12-03 | PFIZER INC. | $2,350 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2019 |
| 2019-12-03 | Genentech, Inc. | $1,754 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2019 |
| 2019-12-03 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB | 2019 |
| 2019-12-03 | F. Hoffmann-La Roche AG | $1,000 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC DX ALL COMER SQUAMOUS | 2019 |
| 2019-12-03 | BIOVERATIV THERAPEUTICS INC. | $1,000 | Research payment | Cash or cash equivalent | BIVV003 Drug | A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantati | 2019 |
| 2019-12-03 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2019 |
| 2019-12-03 | PFIZER INC. | $732 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2019 |
| 2019-12-03 | Eisai Inc. | $400 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-12-03 | PFIZER INC. | $250 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB | 2019 |
| 2019-12-03 | Genentech, Inc. | $80 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2019 |
| 2019-12-02 | Regeneron Pharmaceuticals, Inc. | $4,212 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-12-02 | Genentech, Inc. | $608 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | LCMC3 | 2019 |
| 2019-12-02 | Genentech, Inc. | $352 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | LCMC3 | 2019 |
| 2019-12-02 | Janssen Research & Development, LLC | $316 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2019 | |
| 2019-11-29 | Janssen Research & Development, LLC | $5,594 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subject | 2019 | |
| 2019-11-29 | Janssen Research & Development, LLC | $3,474 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-11-28 | Pharmacyclics LLC, an AbbVie Company | $1,500 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1140-IM | 2019 |
| 2019-11-28 | Pharmacyclics LLC, an AbbVie Company | $1,000 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1140-IM | 2019 |
| 2019-11-28 | Pharmacyclics LLC, an AbbVie Company | $660 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1140-IM | 2019 |
| 2019-11-27 | Exelixis Inc. | $33,672 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-11-27 | Radius Health, Inc. | $15,950 | Research payment | Cash or cash equivalent | A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT RAD1901 VERSUS INVESTIGATOR'S CHOICE OF FULVESTRANT OR AROMATASE | 2019 | |
| 2019-11-27 | PFIZER INC. | $2,275 | Research payment | Cash or cash equivalent | INLYTA Drug, ONCOLOGY | A PHASE 1B OPEN LABEL DOSE FINDING STUDY TO EVALUATE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB AG013736 I | 2019 |
| 2019-11-27 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | INLYTA Drug, ONCOLOGY | A PHASE 1B OPEN LABEL DOSE FINDING STUDY TO EVALUATE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB AG013736 I | 2019 |
| 2019-11-27 | ABBVIE INC. | $1,384 | Research payment | Cash or cash equivalent | Venclexta Drug, Virology | M13-494 | 2019 |
| 2019-11-26 | Merck Sharp & Dohme LLC | $9,359 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2019 |
| 2019-11-26 | Kite Pharma, Inc. | $8,776 | Research payment | Cash or cash equivalent | Yescarta Drug, ONC | PA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non | 2019 |
| 2019-11-26 | Kite Pharma, Inc. | $6,279 | Research payment | Cash or cash equivalent | Yescarta Drug, ONC | PA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non | 2019 |
| 2019-11-26 | Exelixis Inc. | $3,884 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-11-26 | Exelixis Inc. | $3,884 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-11-26 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R | 2019 |
| 2019-11-26 | Plexxikon Inc. | $1,500 | Research payment | Cash or cash equivalent | A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors | 2019 | |
| 2019-11-26 | Plexxikon Inc. | $1,500 | Research payment | Cash or cash equivalent | PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors | 2019 | |
| 2019-11-26 | Kite Pharma, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma | 2019 | |
| 2019-11-26 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-11-26 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-11-26 | Exelixis Inc. | $760 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-11-26 | Merck Sharp & Dohme LLC | $660 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-11-26 | Exelixis Inc. | $650 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-11-26 | Exelixis Inc. | $650 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-11-26 | Exelixis Inc. | $213 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2019 |
| 2019-11-26 | Merck Sharp & Dohme LLC | $123 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Phase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-1 | 2019 |
| 2019-11-25 | Janssen Research & Development, LLC | $34,870 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject | 2019 | |
| 2019-11-25 | Alkermes, Inc. | $4,600 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-11-25 | Alkermes, Inc. | $4,300 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-11-25 | Alkermes, Inc. | $4,000 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-11-25 | Alkermes, Inc. | $4,000 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-11-25 | Alkermes, Inc. | $3,700 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-11-25 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | POLARIX | 2019 |
| 2019-11-25 | Genentech, Inc. | $1,320 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | POLARIX | 2019 |
| 2019-11-25 | Kite Pharma, Inc. | $163 | Research payment | Cash or cash equivalent | Yescarta Drug, ONC | PA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non | 2019 |
| 2019-11-25 | Alkermes, Inc. | $56 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-11-25 | Alkermes, Inc. | $56 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2019 | |
| 2019-11-24 | Merck Sharp & Dohme LLC | $191 | Research payment | In-kind items and services | MK-4280 Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects | 2019 |
The latest 200 records of 2,821.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments